Cargando…

NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET

Treatment planning and lesion-follow up are generally conducted by contrast-enhanced MRI in glioma patient care. On the other hand, there are, however, substantial concerns whether MRI actually reflects the extension or activity of this neoplasm, which information should be fundamentally important a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Manabu, Ozaki, Tomohiko, Arita, Hideyuki, Kagawa, Naoki, Kanemura, Yonehiro, Fujimoto, Yasunori, Sakai, Mio, Watanabe, Yoshiyuki, Nakanishi, Katsuyuki, Shimosegawa, Eku, Hatazawa, Jun, Kishima, Haruhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213347/
http://dx.doi.org/10.1093/noajnl/vdz039.120
_version_ 1783531785651486720
author Kinoshita, Manabu
Ozaki, Tomohiko
Arita, Hideyuki
Kagawa, Naoki
Kanemura, Yonehiro
Fujimoto, Yasunori
Sakai, Mio
Watanabe, Yoshiyuki
Nakanishi, Katsuyuki
Shimosegawa, Eku
Hatazawa, Jun
Kishima, Haruhiko
author_facet Kinoshita, Manabu
Ozaki, Tomohiko
Arita, Hideyuki
Kagawa, Naoki
Kanemura, Yonehiro
Fujimoto, Yasunori
Sakai, Mio
Watanabe, Yoshiyuki
Nakanishi, Katsuyuki
Shimosegawa, Eku
Hatazawa, Jun
Kishima, Haruhiko
author_sort Kinoshita, Manabu
collection PubMed
description Treatment planning and lesion-follow up are generally conducted by contrast-enhanced MRI in glioma patient care. On the other hand, there are, however, substantial concerns whether MRI actually reflects the extension or activity of this neoplasm, which information should be fundamentally important at every step when treating this disease. As a matter of fact, the authors of this investigation have already shown that there is no difference in tumor cell density within areas with and without contrast enhancement (J Neurosurg. 2016,125(5):1136–1142.) and furthermore that the geometry of MRI based-radiation treatment planning is significantly altered when methionine PET is integrated for this purpose (J Neurosurg. 2018 published on-line). Regardless of these concerns, there is great interest in the research community to construct a machine learning based fully automated brain tumor segmentation tool specific for gliomas using MRI. The authors attempted to validate this method by comparing MRI-based automated brain tumor segmentation and methionine PET. Consecutively collected 45 high-grade gliomas (GBM-26, grade3-19) were analyzed. BraTumIA, an automated brain tumor segmentation tool, was used for machine learning based lesion segmentation. At the same time, lesions were segmented using various thresholds on methionine PET. The authors observed 40% of pseudo-positive and 90% of pseudo-negative error on BraTumIA based lesion segmentation when methionine PET was considered as ground truth with a cut-off of 1.3 in T/N ratio. Pseudo-negative error was as high as 60% even if the threshold was elevated to 2.0. Although machine learning based glioma segmentation is expected to expand in both research and clinical use, the observed results caution the use of MRI as ground truth of spatial extension of glioma and researchers should be reminded that this imaging modality may obscure the true behavior of the disease within the patient in some cases.
format Online
Article
Text
id pubmed-7213347
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72133472020-07-07 NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET Kinoshita, Manabu Ozaki, Tomohiko Arita, Hideyuki Kagawa, Naoki Kanemura, Yonehiro Fujimoto, Yasunori Sakai, Mio Watanabe, Yoshiyuki Nakanishi, Katsuyuki Shimosegawa, Eku Hatazawa, Jun Kishima, Haruhiko Neurooncol Adv Abstracts Treatment planning and lesion-follow up are generally conducted by contrast-enhanced MRI in glioma patient care. On the other hand, there are, however, substantial concerns whether MRI actually reflects the extension or activity of this neoplasm, which information should be fundamentally important at every step when treating this disease. As a matter of fact, the authors of this investigation have already shown that there is no difference in tumor cell density within areas with and without contrast enhancement (J Neurosurg. 2016,125(5):1136–1142.) and furthermore that the geometry of MRI based-radiation treatment planning is significantly altered when methionine PET is integrated for this purpose (J Neurosurg. 2018 published on-line). Regardless of these concerns, there is great interest in the research community to construct a machine learning based fully automated brain tumor segmentation tool specific for gliomas using MRI. The authors attempted to validate this method by comparing MRI-based automated brain tumor segmentation and methionine PET. Consecutively collected 45 high-grade gliomas (GBM-26, grade3-19) were analyzed. BraTumIA, an automated brain tumor segmentation tool, was used for machine learning based lesion segmentation. At the same time, lesions were segmented using various thresholds on methionine PET. The authors observed 40% of pseudo-positive and 90% of pseudo-negative error on BraTumIA based lesion segmentation when methionine PET was considered as ground truth with a cut-off of 1.3 in T/N ratio. Pseudo-negative error was as high as 60% even if the threshold was elevated to 2.0. Although machine learning based glioma segmentation is expected to expand in both research and clinical use, the observed results caution the use of MRI as ground truth of spatial extension of glioma and researchers should be reminded that this imaging modality may obscure the true behavior of the disease within the patient in some cases. Oxford University Press 2019-12-16 /pmc/articles/PMC7213347/ http://dx.doi.org/10.1093/noajnl/vdz039.120 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Kinoshita, Manabu
Ozaki, Tomohiko
Arita, Hideyuki
Kagawa, Naoki
Kanemura, Yonehiro
Fujimoto, Yasunori
Sakai, Mio
Watanabe, Yoshiyuki
Nakanishi, Katsuyuki
Shimosegawa, Eku
Hatazawa, Jun
Kishima, Haruhiko
NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET
title NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET
title_full NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET
title_fullStr NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET
title_full_unstemmed NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET
title_short NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET
title_sort ni-07 validation of machine learning based high grade glioma mr segmentation via methionine pet
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213347/
http://dx.doi.org/10.1093/noajnl/vdz039.120
work_keys_str_mv AT kinoshitamanabu ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT ozakitomohiko ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT aritahideyuki ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT kagawanaoki ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT kanemurayonehiro ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT fujimotoyasunori ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT sakaimio ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT watanabeyoshiyuki ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT nakanishikatsuyuki ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT shimosegawaeku ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT hatazawajun ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet
AT kishimaharuhiko ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet